Empagliflozin targeted the immune-related gene PIK3CA in type 2 diabetes mellitus treatment: network pharmacology analysis and experimental evidence.

ABSTRACT:

Background

Type 2 diabetes mellitus (T2DM) is linked to elevated blood glucose due to insulin resistance. Empagliflozin has demonstrated efficacy in T2DM management, with potential immune-modulatory effects. This study aimed to investigate the immune-related mechanisms of empagliflozin in T2DM treatment.

Methods

Gene expression profiles were obtained from common databases, and immune-related differentially expressed genes (IRDEGs) were identified using the "limma" R package. The STRING database and Cytoscape software were utilized to construct a protein-protein interaction network and identify key IRDEGs. Molecular docking was performed to predict the interaction between empagliflozin and PIK3CA. Pathways related to PIK3CA were explored using GSEA, and relationship of PIK3CA

SUBMITTER: Zhong H 

PROVIDER: S-EPMC12330028 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature